Hyogo Cancer Center

Akashi-shi 673-8558

4 studies enrolling now · 7 studies all time

What they study most

BRCA Mutated, CRC (Colorectal Cancer), Endometrial Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Head and Neck Cancer, Ovarian Cancer, Platinum Sensitive, Relapsed Ovarian Cancer, Solid Cancer

Studies at this site

• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
• Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer — Recruiting now
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy — Running, not enrolling
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC — Completed